NLRP3 and myelodysplastic syndrome: Clinical trials of inflammation-targeted therapies are underway for patients with MDS [338], including TLR signaling inhibition [339,340], MDSC elimination [341], NLRP3 inflammasome inhibition [342], and IL-1β inhibition [343].